hims tirzepatide & Hers to sell Lilly's weight-loss drug on its telehealth platform Hims & Hers Expands Weight
Description
We dont have those super-long outcomes studies that you have for bariatric surgery to prove every point, Alexander says
NCT04881760 U.S
Tirzepatide is a dual-agonist peptide researched for its interaction with both GLP-1 receptors and GIP receptors
I get medically accurate guidance
2025;39(2):e1534
Further studies will be needed to see if tirzepatide drugs, like Zepbound, also increase the risk of blood clots and DVT, which can lead to pulmonary embolisms
